Zacks Research Analysts Increase Earnings Estimates for CPRX

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Zacks Research increased their Q1 2025 EPS estimates for shares of Catalyst Pharmaceuticals in a note issued to investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $0.49 per share for the quarter, up from their prior estimate of $0.44. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.53 EPS, Q1 2026 earnings at $0.57 EPS, Q2 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.57 EPS.

Several other equities analysts have also weighed in on the stock. Bank of America reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $24.23 on Friday. The firm has a market capitalization of $2.94 billion, a PE ratio of 20.53, a PEG ratio of 3.31 and a beta of 0.84. The company’s 50-day moving average is $22.39 and its 200-day moving average is $21.62. Catalyst Pharmaceuticals has a fifty-two week low of $14.47 and a fifty-two week high of $24.64.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC increased its stake in Catalyst Pharmaceuticals by 7.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,419 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 1,402 shares during the last quarter. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $3,733,000. Armis Advisers LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $306,000. Finally, Mackenzie Financial Corp increased its stake in Catalyst Pharmaceuticals by 132.9% in the fourth quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 19,705 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.